Hospital
Kuakini Medical Center
Kuakini Medical Center was paid $10.94M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoKUAKINI MEDICAL CENTER
HONOLULU, HI 96817
HONOLULU, HI 96817
33aNPI1215939335assigned 06/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.94M
24GClaims226,514
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Hawaii
Rank by total paid#10 of 18
Median peer was paid$10.94M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,177 | $1.44M | |
| 2019 | 31,807 | $1.34M | |
| 2020 | 20,612 | $922K | |
| 2021 | 29,988 | $1.40M | |
| 2022 | 29,990 | $1.35M | |
| 2023 | 32,233 | $1.46M | |
| 2024incomplete | 27,707 | $3.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 3,287 | 3,008 | $2.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 6,497 | 5,900 | $1.78M |
| G0378 | Hospital observation service, per hour | 14% | 1,829 | 1,536 | $1.53M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 6,199 | 5,530 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.9% | 1,387 | 1,264 | $979K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 2,574 | 2,411 | $728K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 2,473 | 2,303 | $472K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.4% | 1,373 | 1,296 | $367K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 513 | 483 | $323K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 1,723 | 1,557 | $262K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 5,059 | 3,255 | $231K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 361 | 348 | $146K |
128 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 28 | $81K |
| A4649 | Surgical supply; miscellaneous | <1% | 1,171 | $49K |
| 83880 | <1% | 2,994 | $30K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,348 | $27K |
| 80053 | Comprehensive metabolic panel | <1% | 1,610 | $23K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,386 | $15K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 205 | $15K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 136 | $14K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 90 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,995 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,169 | $8K |
| 87040 | <1% | 3,751 | $5K | |
| 87631 | <1% | 2,220 | $4K | |
| 72100 | <1% | 215 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,653 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 69 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,498 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,157 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,923 | $2K |
| 83605 | <1% | 4,337 | $2K | |
| 80306 | <1% | 1,713 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 802 | $2K |
| 73560 | <1% | 214 | $1K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,315 | $954.82 |
| 96367 | <1% | 534 | $755.82 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 20 | $755.20 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,355 | $642.54 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,443 | $573.55 |
| 73130 | <1% | 29 | $555.62 | |
| 85730 | <1% | 2,253 | $343.94 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,654 | $302.19 |
| 73610 | <1% | 13 | $264.83 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 820 | $203.39 |
| 93017 | <1% | 26 | $170.50 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,820 | $155.13 |
| 73630 | <1% | 29 | $146.59 | |
| 73030 | <1% | 54 | $134.77 | |
| A9270 | Non-covered item or service | <1% | 21,277 | $86.66 |
| 96160 | <1% | 528 | $57.02 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 377 | $55.79 |
| 90715 | <1% | 111 | $38.75 | |
| 81001 | <1% | 5,858 | $25.16 | |
| 83690 | <1% | 3,769 | $18.24 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,306 | $12.80 |
| 81025 | <1% | 751 | $12.30 | |
| 84484 | <1% | 6,067 | $8.47 | |
| 86850 | <1% | 37 | $8.12 | |
| 87186 | <1% | 885 | $7.51 | |
| 80076 | <1% | 3,966 | $6.38 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,812 | $6.00 |
| 83735 | <1% | 3,315 | $5.96 | |
| 82550 | <1% | 463 | $5.79 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 106 | $4.46 |
| 85610 | <1% | 4,404 | $3.49 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,084 | $1.18 |
| 82374 | 0% | 2,383 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 217 | $0.00 |
| 84100 | 0% | 1,636 | $0.00 | |
| 82948 | 0% | 2,504 | $0.00 | |
| 82310 | 0% | 2,282 | $0.00 | |
| 82565 | 0% | 2,391 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 2,805 | $0.00 |
| 84460 | 0% | 886 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 450 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 15 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 506 | $0.00 |
| 84295 | 0% | 2,391 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 381 | $0.00 |
| 88312 | 0% | 25 | $0.00 | |
| 97161 | 0% | 41 | $0.00 | |
| 82947 | 0% | 2,347 | $0.00 | |
| 82248 | 0% | 724 | $0.00 | |
| 84520 | 0% | 2,398 | $0.00 | |
| 84155 | 0% | 886 | $0.00 | |
| 84450 | 0% | 885 | $0.00 | |
| 82247 | 0% | 884 | $0.00 | |
| 99152 | 0% | 14 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 113 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 40 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 90 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 17 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 21 | $0.00 |
| 84145 | 0% | 76 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 14 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 86900 | 0% | 36 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 13 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 12 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,469 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,281 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,068 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,700 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,309 | $0.00 |
| 96376 | 0% | 1,281 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 33 | $0.00 |
| 84703 | 0% | 566 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,607 | $0.00 |
| 84132 | 0% | 2,396 | $0.00 | |
| 82150 | 0% | 27 | $0.00 | |
| 82553 | 0% | 101 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 282 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,393 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 173 | $0.00 |
| 82040 | 0% | 887 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 180 | $0.00 |
| 87205 | 0% | 187 | $0.00 | |
| 88304 | 0% | 178 | $0.00 | |
| 82435 | 0% | 2,383 | $0.00 | |
| 87077 | 0% | 464 | $0.00 | |
| 86901 | 0% | 36 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 51 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 44 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 49 | $0.00 |
| 87070 | 0% | 112 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 14 | $0.00 |
| 87071 | 0% | 60 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 16 | $0.00 |
| 87088 | 0% | 132 | $0.00 | |
| 84075 | 0% | 885 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 13 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 14 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 67 | $0.00 |
| 94760 | 0% | 32 | $0.00 | |
| 80051 | 0% | 13 | $0.00 | |
| 97165 | 0% | 29 | $0.00 | |
| 85379 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAJIWARA, GARY (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Kuakini Support Services, INC. | Honolulu, HI | $755.53 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.